FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4295836812> ?p ?o ?g. }

• W4295836812 endingPage "S1307" @default.
• W4295836812 startingPage "S1306" @default.
• W4295836812 abstract "The rapid identification of disease progression in patients receiving immune checkpoint inhibitors (ICIs) is challenging using methods that rely on imaging assessments. Here, we investigated genome-wide cell-free DNA (cfDNA) fragmentation profiles to molecularly detect disease progression in the phase I study of entinostat and nivolumab +/- ipilimumab in advanced solid tumors (ETCTN-9844, NCT02453620). Patients with metastatic or unresectable solid tumors received an entinostat run-in 2 weeks prior to the addition of anti-PD-1 and anti-CTLA-4 ICIs. Blood was collected at baseline (50/50 patients) and at 10 weeks after treatment initiation (27/50 patients). Low-coverage (1-2x) whole genome sequencing was performed on cfDNA from plasma samples. Genome-wide cfDNA fragmentation features were included in a Bayesian model to approximate a tumor fraction as compared to best response by RECIST v1.1. Molecular response was defined as reduction (≥ 30%) of the fragmentation based tumor fraction between the baseline and 10-week time point. 50 patients with breast (n = 28), salivary gland (n = 7), gastrointestinal (n = 6), gynecological (n = 4), sarcoma (n = 3), and lung cancer (n = 2) received a median of 4 prior lines of therapy (0-14). Response assessment using molecular analyses and best overall response by RECIST were reported at a mean of 9.3 (5-10.7) and 14.3 weeks (5-73). Molecular responders and non-responders at week 10 experienced a median PFS that was not reached (NR) and 4.5 months (HR = 5.4; 95% CI 1.7-17; p = 0.004) while patients with RECIST response and non-response at week 10 had similar PFS (median 6.4 vs. 6.7 months; HR = 1.7; 95% CI 0.54-5.3; p = 0.36). Among the subgroup of radiographic non-responders with stable disease, PFS for molecular responders was NR while for molecular non-responders it was 5.2 months (p = 0.021). There is a clinical need for non-invasive tests to identify primary or acquired resistance to ICIs, sparing patients from ineffective treatments associated with immune-related adverse events. Here, we demonstrate a cfDNA fragmentation based approach for molecular detection of disease progression that could guide future trials with ICIs." @default.
• W4295836812 created "2022-09-15" @default.
• W4295836812 creator A5004542056 @default.
• W4295836812 creator A5006560755 @default.
• W4295836812 creator A5018468153 @default.
• W4295836812 creator A5022022603 @default.
• W4295836812 creator A5023416292 @default.
• W4295836812 creator A5024038310 @default.
• W4295836812 creator A5024278640 @default.
• W4295836812 creator A5031698463 @default.
• W4295836812 creator A5034156947 @default.
• W4295836812 creator A5036018104 @default.
• W4295836812 creator A5039068387 @default.
• W4295836812 creator A5044108002 @default.
• W4295836812 creator A5046042179 @default.
• W4295836812 creator A5049478087 @default.
• W4295836812 creator A5051641247 @default.
• W4295836812 creator A5053611592 @default.
• W4295836812 creator A5056530735 @default.
• W4295836812 creator A5075650701 @default.
• W4295836812 creator A5084214387 @default.
• W4295836812 creator A5090809833 @default.
• W4295836812 date "2022-09-01" @default.
• W4295836812 modified "2023-09-26" @default.
• W4295836812 title "1669P Monitoring immune checkpoint inhibition in advanced solid tumors using genome-wide cfDNA fragmentomes" @default.
• W4295836812 doi "https://doi.org/10.1016/j.annonc.2022.07.1749" @default.
• W4295836812 hasPublicationYear "2022" @default.
• W4295836812 type Work @default.
• W4295836812 citedByCount "1" @default.
• W4295836812 countsByYear W42958368122023 @default.
• W4295836812 crossrefType "journal-article" @default.
• W4295836812 hasAuthorship W4295836812A5004542056 @default.
• W4295836812 hasAuthorship W4295836812A5006560755 @default.
• W4295836812 hasAuthorship W4295836812A5018468153 @default.
• W4295836812 hasAuthorship W4295836812A5022022603 @default.
• W4295836812 hasAuthorship W4295836812A5023416292 @default.
• W4295836812 hasAuthorship W4295836812A5024038310 @default.
• W4295836812 hasAuthorship W4295836812A5024278640 @default.
• W4295836812 hasAuthorship W4295836812A5031698463 @default.
• W4295836812 hasAuthorship W4295836812A5034156947 @default.
• W4295836812 hasAuthorship W4295836812A5036018104 @default.
• W4295836812 hasAuthorship W4295836812A5039068387 @default.
• W4295836812 hasAuthorship W4295836812A5044108002 @default.
• W4295836812 hasAuthorship W4295836812A5046042179 @default.
• W4295836812 hasAuthorship W4295836812A5049478087 @default.
• W4295836812 hasAuthorship W4295836812A5051641247 @default.
• W4295836812 hasAuthorship W4295836812A5053611592 @default.
• W4295836812 hasAuthorship W4295836812A5056530735 @default.
• W4295836812 hasAuthorship W4295836812A5075650701 @default.
• W4295836812 hasAuthorship W4295836812A5084214387 @default.
• W4295836812 hasAuthorship W4295836812A5090809833 @default.
• W4295836812 hasConcept C121608353 @default.
• W4295836812 hasConcept C126322002 @default.
• W4295836812 hasConcept C143998085 @default.
• W4295836812 hasConcept C2777701055 @default.
• W4295836812 hasConcept C2778822529 @default.
• W4295836812 hasConcept C2779134260 @default.
• W4295836812 hasConcept C2779984678 @default.
• W4295836812 hasConcept C2780030458 @default.
• W4295836812 hasConcept C2780265364 @default.
• W4295836812 hasConcept C2781433595 @default.
• W4295836812 hasConcept C71924100 @default.
• W4295836812 hasConcept C90924648 @default.
• W4295836812 hasConceptScore W4295836812C121608353 @default.
• W4295836812 hasConceptScore W4295836812C126322002 @default.
• W4295836812 hasConceptScore W4295836812C143998085 @default.
• W4295836812 hasConceptScore W4295836812C2777701055 @default.
• W4295836812 hasConceptScore W4295836812C2778822529 @default.
• W4295836812 hasConceptScore W4295836812C2779134260 @default.
• W4295836812 hasConceptScore W4295836812C2779984678 @default.
• W4295836812 hasConceptScore W4295836812C2780030458 @default.
• W4295836812 hasConceptScore W4295836812C2780265364 @default.
• W4295836812 hasConceptScore W4295836812C2781433595 @default.
• W4295836812 hasConceptScore W4295836812C71924100 @default.
• W4295836812 hasConceptScore W4295836812C90924648 @default.
• W4295836812 hasLocation W42958368121 @default.
• W4295836812 hasOpenAccess W4295836812 @default.
• W4295836812 hasPrimaryLocation W42958368121 @default.
• W4295836812 hasRelatedWork W2936810997 @default.
• W4295836812 hasRelatedWork W2973740076 @default.
• W4295836812 hasRelatedWork W3035208766 @default.
• W4295836812 hasRelatedWork W3095042835 @default.
• W4295836812 hasRelatedWork W3120622126 @default.
• W4295836812 hasRelatedWork W3181034934 @default.
• W4295836812 hasRelatedWork W4281619570 @default.
• W4295836812 hasRelatedWork W4295272945 @default.
• W4295836812 hasRelatedWork W4295817426 @default.
• W4295836812 hasRelatedWork W4295817599 @default.
• W4295836812 hasVolume "33" @default.
• W4295836812 isParatext "false" @default.
• W4295836812 isRetracted "false" @default.
• W4295836812 workType "article" @default.